학술논문

Microperimetry to predict disease progression in eyes at high risk of age‐related macular degeneration disease: The PREVISION study.
Document Type
Article
Source
Acta Ophthalmologica (1755375X). Mar2023, Vol. 101 Issue 2, pe135-e142. 8p.
Subject
*MACULAR degeneration
*DISEASE progression
*MULTIVARIATE analysis
Language
ISSN
1755-375X
Abstract
Purpose: The aim of the present study was to determine whether microperimetric parameters could predict the progression of an eye at high risk of age‐related macular degeneration (AMD) at 24 months. Methods: We conducted a multicentric prospective non‐comparative open‐label study including patients with one eye in stage 4 of the Age‐Related Eye Disease Study Group (AREDS) classification, and the other eye in AREDS stage 3 (study eye). A microperimetry examination (MAIA™, CenterVue, Padova, Italy) was performed at baseline and every 6 months during the 2‐year follow‐up. At the end of the follow‐up, each study eye was classified as 'progressive' (i.e. AREDS stage 4) or 'non‐progressive' (i.e. AREDS stage 3). Results: A total of 147 patients were analysed, of which 30.6% progressed from AREDS stage 3 to stage 4. The microperimetry criterion 'mean retinal sensitivity' was significantly different at baseline between non‐progressive and progressive eyes (p = 0.022), with lower values for the latter. With a threshold for mean retinal sensitivity set at 24.7 dB, diagnostic sensitivity was 80% [95%CI (65.4–90.4)], specificity was 30.4% [95%CI (21.7–40.3)], positive predictive value was 33.6% [95%CI (24.8–43.4)], and negative predictive value was 77.5% [95%CI (61.5–89.2)]. In the multivariate analysis including microperimetric parameters and other routine ophthalmologic examinations, mean retinal sensitivity was the only predictive parameter statistically associated with progression (p = 0.0004). Conclusions: Our findings are encouraging as regards the use of microperimetry, and mean retinal sensitivity value in particular, to predict the 2‐year risk of progression to AREDS stage 4 eye. [ABSTRACT FROM AUTHOR]